MedTrace Logo

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

NCT07413835 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-03-18

No results posted yet for this study

Summary

This is an open label, single arm study, to evaluate the safety , tolerability and preliminary efficacy of HN2302 for refractory myasthenia gravis.

Conditions

  • Refractory Myasthenia Gravis

Interventions

DRUG

HN2302 Injection

Patients will be administrated with specified dose on specified days at a lower dose level and escalated to safe and effective dose levels.

Sponsors & Collaborators

  • Shenzhen MagicRNA Biotechnology Co., Ltd

    collaborator INDUSTRY

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Guiyun Cui · The Affiliated Hospital of Xuzhou Medical University

  • Yong Zhang · The Affiliated Hospital of Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07413835 on ClinicalTrials.gov